<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076515</url>
  </required_header>
  <id_info>
    <org_study_id>TCH_002</org_study_id>
    <nct_id>NCT03076515</nct_id>
  </id_info>
  <brief_title>Migraine Treatment With Nerivio Migra Neurostimulation Device</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Sham Controlled Multi-center Clinical Trial, Migraine Headache Treatment With Nerivio Migra Neurostimulation Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio&#xD;
      between treatment and control groups will be 1:1, stratified by center and use of preventive&#xD;
      medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, sham controlled multi-center clinical trial&#xD;
      &quot;Migraine Treatment with Nerivio Migra electro stimulation device&quot;. The study will enroll up&#xD;
      to 248 patients diagnosed with migraine with and without aura, per the inclusion and&#xD;
      exclusion criteria. These patients will be individually and randomly assigned to either&#xD;
      treatment group or control group. For sham control, short electrical pulses of amplitude&#xD;
      range similar to that of the treatment programs will be administered at very low frequency&#xD;
      (0.1-0.5 Hz). The rationale underlying selection of sham control settings is that, on the one&#xD;
      hand, pulses are perceivable and the user is able to manipulate their intensity similarly to&#xD;
      the case of treatment programs, while, on the other hand, no clinically relevant treatment is&#xD;
      delivered, based on existing knowledge of parameters range of electro stimulation treatments×¥&#xD;
&#xD;
      Following successful screening, enrollment interview and signing of informed consent,&#xD;
      participants will be provided with an active Nerivio Migra or identically looking sham device&#xD;
      and trained to perform treatment and provide feedback via the smartphone application. Ratio&#xD;
      between treatment and control groups will be 1:1.&#xD;
&#xD;
      Baseline information including mean frequency and severity of migraine attacks, occurrence of&#xD;
      other headaches, presence of ICHD-3 diagnostic criteria for migraine with and without aura&#xD;
      and use of preventive and rescue medications will be recorded.&#xD;
&#xD;
      Investigational devices will be programmed in active or sham mode with a 1:1 ratio, in order&#xD;
      to achieve the desired ratio between active and control groups sizes.&#xD;
&#xD;
      Stage One. In stage one (roll-in phase) recruited participants will be reporting their&#xD;
      migraine attacks per ICHD-3 diagnostic criteria, including presence of aura, using an&#xD;
      electronic migraine diary installed on their smartphones. Duration of this phase is one&#xD;
      month.&#xD;
&#xD;
      Participants that will report less than 2 or more than 8 migraine attacks during the roll-in&#xD;
      period will be excluded from the treatment phase.&#xD;
&#xD;
      Stage Two. This will be the parallel arm treatment stage. Participants will be instructed to&#xD;
      activate the device at onset of a qualifying migraine attack and manually adjust stimulation&#xD;
      intensity to a level within the pre-defined range where it is well perceived but not painful.&#xD;
      A qualifying migraine attack shall be preceded by at least 48 hours of freedom from headache.&#xD;
      Patients will be requested to refrain from use of rescue medications prior to and during the&#xD;
      first two hours after treatment with the device, and if they can not comply with this, record&#xD;
      their use of rescue medications (migraine specific drugs or other medications or therapies&#xD;
      that may be used to treat pain, from a pre-specified list) in the mobile application.&#xD;
&#xD;
      Via the smartphone application, each participant will be asked to rate his/her migraine pain&#xD;
      level three times using Pain Grades Scale (0 - no pain, 1- mild pain, 2- moderate pain, 3 -&#xD;
      severe pain): (1) upon starting the treatment, (2) two hours after start of treatment, (3) 48&#xD;
      hours after start of attack. At the start of each treatment, participants will be also asked&#xD;
      to provide time elapsed from start of migraine attack to start of the treatment. Participants&#xD;
      will be also asked to provide feedback regarding their use of medication (migraine specific&#xD;
      drugs or other medications or therapies that may be used to treat pain, from a pre-specified&#xD;
      list), presence of nausea, photophobia and phonophobia, and treatment perception. After&#xD;
      providing feedback at two hours after start of treatment and in case of pain recurrence,&#xD;
      participants will be allowed to re-treat the attack using Migra device.&#xD;
&#xD;
      Adverse events will be reported. Duration of study participation for each patient will be up&#xD;
      to three months, determined by one month of the roll-in stage followed treatment of four&#xD;
      qualifying attacks over the course of two months (whichever is achieved first).&#xD;
&#xD;
      Post study questionnaire will include patient global impression of change, blinding and&#xD;
      usability assessments.&#xD;
&#xD;
      Stage Three. This part will include open label extended treatment. Following the completion&#xD;
      of the study by all subjects and the return of all study devices, subjects will be offered a&#xD;
      2-month period of using active device, at no cost.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was prematurely stop based on DMC recommendation&#xD;
  </why_stopped>
  <start_date type="Actual">April 2, 2017</start_date>
  <completion_date type="Actual">April 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Pain Relief 2 Hours Post Treatment</measure>
    <time_frame>2 hours post treatment</time_frame>
    <description>Percentage of participants reporting pain relief from pain (pain reduction from 3 or 2 to 1 or 0 or pain reduction from 1 to 0) 2 hours post treatment without rescue medications in at least 50% of treated attacks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Nerivio Migra active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerivio Migra placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nerivio Migra neurostimulation</intervention_name>
    <description>transcutaneous electrical stimulation</description>
    <arm_group_label>Nerivio Migra active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Nerivio Migra</intervention_name>
    <description>electrical stimulation- shame mode</description>
    <arm_group_label>Nerivio Migra placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is 18-75 years old.&#xD;
&#xD;
          2. Patient meeting the ICHD-3 diagnostic criteria for migraine with and without aura.&#xD;
&#xD;
          3. Patients reporting 2-8 migraine attacks per month.&#xD;
&#xD;
          4. Patient must be able and willing to comply with the protocol.&#xD;
&#xD;
          5. Patient must be able and willing to provide written informed consent.&#xD;
&#xD;
          6. Male or non-pregnant / non-lactating female (NOTE: Females of child bearing potential&#xD;
             must have a negative pregnancy test) and must be willing to use adequate contraceptive&#xD;
             means during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has other significant pain problem that in the opinion of the investigator may&#xD;
             confound the study assessments&#xD;
&#xD;
          2. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac&#xD;
             pacemaker or defibrillator, vagus nerve neurostimulator, deep brain stimulator, spinal&#xD;
             stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion&#xD;
             stimulator or Occipital nerve stimulator).&#xD;
&#xD;
          3. Known uncontrolled epilepsy.&#xD;
&#xD;
          4. Use of Cannabis including medical use.&#xD;
&#xD;
          5. Has chronic migraine (more than 15 headache days per month).&#xD;
&#xD;
          6. Changed usage or dosage of migraine preventive medications in the last two months&#xD;
&#xD;
          7. Has undergone nerve block (occipital or other) in the head or neck within the last 2&#xD;
             weeks.&#xD;
&#xD;
          8. Is participating in any other clinical study. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Grosberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Healthcare Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedStar - Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Healthcare Headache Center</name>
      <address>
        <city>Hartford</city>
        <state>New York</state>
        <zip>06103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Inc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzeliya medical Center</name>
      <address>
        <city>Herzliya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maccabi Healthcare neurology clinics</name>
      <address>
        <city>Kefar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <results_first_submitted>September 10, 2019</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03076515/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nerivio Migra Active</title>
          <description>Nerivio Migra neurostimulation: transcutaneous electrical stimulation</description>
        </group>
        <group group_id="P2">
          <title>Nerivio Migra Placebo</title>
          <description>Sham Nerivio Migra: electrical stimulation- shame mode</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>DMC decision based on interim analysis</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nerivio Migra Active</title>
          <description>Nerivio Migra neurostimulation: transcutaneous electrical stimulation</description>
        </group>
        <group group_id="B2">
          <title>Nerivio Migra Placebo</title>
          <description>Sham Nerivio Migra: electrical stimulation- shame mode</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="12.9"/>
                    <measurement group_id="B2" value="42.3" spread="12.7"/>
                    <measurement group_id="B3" value="44.8" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine attacks per month</title>
          <units>number of migraine attacks per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="1.2"/>
                    <measurement group_id="B2" value="3.9" spread="1.3"/>
                    <measurement group_id="B3" value="4.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Pain Relief 2 Hours Post Treatment</title>
        <description>Percentage of participants reporting pain relief from pain (pain reduction from 3 or 2 to 1 or 0 or pain reduction from 1 to 0) 2 hours post treatment without rescue medications in at least 50% of treated attacks</description>
        <time_frame>2 hours post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nerivio Migra Active</title>
            <description>Subjects received an active form of Nerivio Migra neurostimulation device</description>
          </group>
          <group group_id="O2">
            <title>Nerivio Migra Placebo</title>
            <description>Subjects received a Sham form of Nerivio Migra: neurostimulation device</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Relief 2 Hours Post Treatment</title>
          <description>Percentage of participants reporting pain relief from pain (pain reduction from 3 or 2 to 1 or 0 or pain reduction from 1 to 0) 2 hours post treatment without rescue medications in at least 50% of treated attacks</description>
          <units>percentage of responded participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nerivio Migra Active</title>
          <description>Nerivio Migra neurostimulation: transcutaneous electrical stimulation</description>
        </group>
        <group group_id="E2">
          <title>Nerivio Migra Placebo</title>
          <description>Sham Nerivio Migra: electrical stimulation- shame mode</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated following an interim analysis based on 25% of the target study sample size (performed at September 3rd, 2017). the DMC decision was &quot;According to the decisions rules planned in the SAP, the study should be stopped for futility&quot;</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dagan Harris</name_or_title>
      <organization>Theranica Bio-Electronics Ltd</organization>
      <phone>+972723909755</phone>
      <email>daganh@theranica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

